


PHARMACEUTICAL 2022



Arbutus Biopharma Corp Rank 171 of 466







PHARMACEUTICAL 2022



Arbutus Biopharma Corp Rank 171 of 466

The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 42% points. The greatest weakness of Arbutus Biopharma Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 180%, being 102% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	160,661
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,221
Liabilities, Non-Current	2,231
Other Assets	37,841
Other Compr. Net Income	-164
Other Expenses	1,872
Other Liabilities	21,594
Other Net Income	-2,725
Other Revenues	10,988
Property and Equipment	5,983
Research and Development	65,502
Selling, General and Administrative Expense	17,136

Output Variable	Value in 1000 USD
Assets	204,485
Liabilities	35,046
Expenses	84,510
Revenues	10,988
Stockholders Equity	169,439
Net Income	-76,247
Comprehensive Net Income	-76,329
Economic Capital Ratio	180%

